SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Izzy who wrote (4774)7/7/1998 10:41:00 AM
From: Bhag Karamchandani  Read Replies (1) of 6136
 
Izzy: I am sorry, if the issues I raise are disconcerting. If and when I take a position in AGPH ( my resources are very limited) I will let you know.I have said that AGPH was undervalued at $35. However,my actions will not be based on price alone. But rather on favorable PIII trial results, at the very least.

At one point Karen Firestone (?) who manages Fidelity Biotech Fund considered AGPH as having the technology platform and a promising pipeline to produce one or may be two drugs each year or two. The question to ask AGPH management is: what happened to all this promise. Instead, all AGPH has done is to announce strategic moves - in the short run they have not helped AGPH shareholders.That does not mean they are not the right ones to make.
Having said all this, not even for a moment, do I seriously believe that what I say (or for that matter others say )on this thread has any impact on the final scheme of things. I do sincerely wish you all good luck.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News